I am a board-certified radiation oncologist with a special interest in treating patients with brain tumors. I specialize in the use of stereotactic radiosurgery, intensity-modulated radiation therapy (IMRT), and conformal radiation therapy to treat both benign and malignant brain tumors precisely and effectively, while minimizing the effects of treatment on nearby healthy tissue. Among the diseases I treat are acoustic neuromas, meningiomas, glioblastomas, anaplastic astrocytomas, low-grade gliomas, oligodendrogliomas, pituitary adenomas, and ependymomas.
I am a member of Memorial Sloan Kettering’s central nervous system disease management team and work closely with neurosurgeons and neuro-oncologists to provide optimal care for our patients. I am also a member of the Brain Tumor Center.
In addition to caring for patients, I am the principal investigator of a cancer genetics laboratory in the Human Oncology and Pathogenesis Program, where my colleagues and I are exploring the genetic changes that lead to cancer. We are dedicated to using our findings on the cancer genome to develop better diagnostic and treatment approaches that will improve the care of people with cancer.
- Clinical Expertise: Malignant and Benign Brain Tumors (Meningiomas, Glioblastomas [Gliomas], Anaplastic Astrocytomas, Low-grade Gliomas, Oligodendrogliomas, Ependymomas); Acoustic Neuromas; Pituitary Tumors; Stereotactic Radiosurgery; Intensity-Modulated Radiation Therapy (IMRT); 3D Conformal Radiation Therapy
- Languages Spoken: English
- Education: MD, PhD, The Johns Hopkins School of Medicine
- Residencies: The Johns Hopkins Hospital
- Fellowships: The Johns Hopkins Hospital
- Board Certifications: Radiation Oncology
Chan TA, Weingart JD, Parisi M, Hughes MA, Olivi A, Borzillary S, Alahakone D, Detorie NA, Wharam MD, Kleinberg L.. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.. Int J Radiat Oncol Biol Phys July 15, 2005; 62(4) :1133-9
Zhou X, Suzuki H, Lei J, Cole K, Yin J, Suzuki V, Abraham JM, Shimada Y, Imamura M, Chan T, Hannon GJ, Meltzer SJ.. Growth suppression of esophageal cancer cells by p16INK4 and p15INK4B in vitro. Cancer J Sci Am. 1996 Jul-Aug;2(4):221-4. December 31, 1996; 2(4) :197-9
Suzuki H, Zhou X, Yin J, Lei J, Jiang HY, Suzuki Y, Chan T, Hannon GJ, Mergner WJ, Abraham JM, et al.. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers.. Hum Mol Genet. October 1995; 4(10) :1883-7
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Co-Investigated by Timothy A. Chan
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more